David C. Myles - 19 Dec 2025 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Signature
/s/ Shane Kovacs, Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
19 Dec 2025
Net transactions value
-$1,553,544
Form type
4
Filing time
23 Dec 2025, 21:41:49 UTC
Previous filing
03 Mar 2025
Next filing
14 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Myles David C. CH. DISCOV. & NON-CLIN DEV OFF C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO /s/ Shane Kovacs, Attorney-in-Fact 23 Dec 2025 0001831216

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale $34,398 -1,225 -0.2% $28.08 601,656 19 Dec 2025 Direct F1, F2, F3
transaction OLMA Common Stock Sale $1,329,362 -43,729 -7.3% $30.40 557,927 19 Dec 2025 Direct F4
transaction OLMA Common Stock Sale $189,784 -6,046 -1.1% $31.39 551,881 19 Dec 2025 Direct F5
transaction OLMA Common Stock Gift $0 -9,000 -1.6% $0.000000 542,881 19 Dec 2025 Direct
holding OLMA Common Stock 12,831 19 Dec 2025 See Footnote F6
holding OLMA Common Stock 154,846 19 Dec 2025 See Footnote F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $28.08, and the range of prices was between $28.075 and $28.130. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F2 On December 11, 2024, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be understated by 60 shares. That error has been corrected in this Form 4.
F3 Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.
F4 The weighted average sale price for the transaction reported was $30.40, and the range of prices was between $30.00 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided
F5 The weighted average sale price for the transaction reported was $31.39, and the range of prices was between $31.00 and $31.595. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F6 The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
F7 The shares are held by Myles Properties Inc., of which the Reporting Person is President.